Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.
Magda Opsomer, MD, director, clinical Leader, Infectious Diseases and Vaccines, Janssen Pharmaceutical Companies, Belgium, provides some insight into the phase 3 EMERALD trial regarding individuals infected with HIV who are suppressed on their treatment. Dr. Opsomer shares that the results are favorable and the fact that it is a single-tablet regimen may work to improve adherence to treatment. Dr. Opsomer also shares some of the “high points” of the study. Recently, Janssen Research & Development submitted a new drug application to the US Food and Drug Administration for the new darunavir-based regimen.